<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Samsung Epis Holdings Co., Ltd. — News on 6ix</title>
    <link>https://6ix.com/company/samsung-epis-holdings-co-ltd</link>
    <description>Latest news and press releases for Samsung Epis Holdings Co., Ltd. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 23 Apr 2026 06:54:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/samsung-epis-holdings-co-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d6457fbeedb30cb6fd2150.webp</url>
      <title>Samsung Epis Holdings Co., Ltd.</title>
      <link>https://6ix.com/company/samsung-epis-holdings-co-ltd</link>
    </image>
    <item>
      <title>Samsung Epis Holdings Reports First Quarter 2026 Financial Results</title>
      <link>https://6ix.com/company/samsung-epis-holdings-co-ltd/news/samsung-epis-holdings-reports-first-quarter-2026-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/samsung-epis-holdings-co-ltd/news/samsung-epis-holdings-reports-first-quarter-2026-financial-results</guid>
      <pubDate>Thu, 23 Apr 2026 06:54:00 GMT</pubDate>
      <description>INCHEON, Korea, April 23, 2026--Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026.</description>
    </item>
    <item>
      <title>Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide</title>
      <link>https://6ix.com/company/samsung-epis-holdings-co-ltd/news/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide</link>
      <guid isPermaLink="true">https://6ix.com/company/samsung-epis-holdings-co-ltd/news/samsung-bioepis-and-epis-nexlab-sign-research-collaboration-and-license-agreement-with-g2gbio-to-develop-novel-assets-including-long-acting-semaglutide</guid>
      <pubDate>Sun, 15 Mar 2026 23:30:00 GMT</pubDate>
      <description>INCHEON, Korea, March 15, 2026--Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: 0126Z0), today announced a research collaboration and license agreement with G2GBIO, a company specializing in the development of sustained-release formulations, to develop novel assets based on G2GBIO’s proprietary microsphere technology.</description>
    </item>
    <item>
      <title>Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results</title>
      <link>https://6ix.com/company/samsung-epis-holdings-co-ltd/news/samsung-epis-holdings-reports-fourth-quarter-and-fiscal-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/samsung-epis-holdings-co-ltd/news/samsung-epis-holdings-reports-fourth-quarter-and-fiscal-year-2025-financial-results</guid>
      <pubDate>Mon, 26 Jan 2026 07:00:00 GMT</pubDate>
      <description>INCHEON, Korea, January 26, 2026--Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025.</description>
    </item>
    <item>
      <title>Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/samsung-epis-holdings-co-ltd/news/samsung-epis-holdings-delivers-business-updates-at-the-44th-jp-morgan-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/samsung-epis-holdings-co-ltd/news/samsung-epis-holdings-delivers-business-updates-at-the-44th-jp-morgan-healthcare-conference</guid>
      <pubDate>Thu, 15 Jan 2026 00:40:00 GMT</pubDate>
      <description>INCHEON, Korea, January 15, 2026--Samsung Epis Holdings shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference.</description>
    </item>
  </channel>
</rss>